Sep 17, 2019 16:42 JST

Source: Eisai

Eisai Receives IIA Japan Chairman's Award of Institute of Internal Auditors - Japan

TOKYO, Sep 17, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received the 33rd "IIA Japan Chairman's Award" of the Institute of Internal Auditors - Japan.

The IIA Japan was established in 1957 with the aim of contributing to the sound development of Japan's industry and economy through the internal audits. It also functions as Japan's representative organization of The Institution of Internal Auditors (IIA), which plays a role of global leadership in international audits.

"IIA Japan Chairman's Award" was established in 1987, and it is the 33rd time this year. This award is to commend the corporations and management organizations, which have the fulfilled internal audit system, the active and continuous internal audit activities in long time period, the achieved results, as well as the contribution for spreading and developing the internal audit.

Through the review by the Review Committee, the following initiatives of Eisai's Corporate Internal Audit Department for the internal audit activities were highly evaluated, and Eisai received the Chairman's Award.

- Emphasis on contribution for achieving the corporate objectives
- Implementation of audit by the full consideration of business operation risks and socially focused matters and selecting the theme for audit
- Emphasis on cause analysis of problems
- Implementation of regular internal and external evaluations for continuous audit quality improvement

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. In order to realize this corporate philosophy, Eisai will promote our initiatives for internal audit quality improvement, and is striving for further enhancement of corporate governance to improve sustainable corporate value.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
March 29 2024 14:32 JST
 
Lifenet and Eisai Co-Develop Dementia Insurance "be"
March 21 2024 16:36 JST
 
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
March 21 2024 15:10 JST
 
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
March 06 2024 16:47 JST
 
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
February 21 2024 14:26 JST
 
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
February 20 2024 08:35 JST
 
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
February 16 2024 08:31 JST
 
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
February 01 2024 17:04 JST
 
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
January 26 2024 15:26 JST
 
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
January 18 2024 14:12 JST
 
More Press release >>

Latest Press Release


More Latest Release >>